Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). (Q38579008)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 September 2015

Language	Label	Description	Also known as
English	Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).	scientific article published on 02 September 2015

Statements

scholarly article

1 reference

Europe PubMed Central

4 September 2017

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). (English)

1 reference

Europe PubMed Central

4 September 2017

0 references

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Barbara Eichhorst

3

object named as

Barbara Eichhorst

0 references

4

object named as

Michael Hallek

1 reference

Europe PubMed Central

4 September 2017

author name string

Paula Cramer

1

1 reference

Europe PubMed Central

4 September 2017

Petra Langerbeins

2

1 reference

Europe PubMed Central

4 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

2 September 2015

1 reference

Europe PubMed Central

4 September 2017

European Journal of Haematology

1 reference

Europe PubMed Central

4 September 2017

96

1 reference

Europe PubMed Central

4 September 2017

1

1 reference

Europe PubMed Central

4 September 2017

9-18

1 reference

Europe PubMed Central

4 September 2017

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Disease burden of chronic lymphocytic leukaemia within the European Union

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Sex differences in incidence and outcome of chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Karyotypic evolution in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Treatment of elderly patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Cumulative illness rating scale

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Targeting the B cell receptor pathway in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Identifiers

10.1111/EJH.12678

1 reference

Europe PubMed Central

4 September 2017

1 reference

Europe PubMed Central

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38579008&oldid=1634910728"